Tuesday June 2, 8:03 am Eastern Time
Company Press Release
SOURCE: The Immune Response Corporation
The Immune Response Corporation Announces Publication of Clinical Data Concerning Immune Responses in Individuals Treated with REMUNE(TM)
CARLSBAD, Calif., June 2 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) today announced the publication of an open label study, involving six HIV-infected individuals, in the American Society for Microbiology, May 1998 issue of the Journal of Clinical and Diagnostic Laboratory Immunology. The company believes this paper, entitled ''In Vitro p24 Antigen Stimulated Lymphocyte Proliferation and b-Chemokine Production After Immunization with an Inactivated gp120-Depleted HIV-1 Immunogen (REMUNE) in HIV-1 Seropositive Subjects,'' may support previous findings regarding the stimulation of specific immune responses to the conserved inner parts of HIV-1 as measured by T cell proliferation and beta-chemokine (''b-chemokine'') production.
Current drug treatment alone appears not to reconstitute the HIV-specific immune response lost after infection with HIV. The HIV-infected individuals studied initially received effective antiviral drug therapy and were then treated with REMUNE. These individuals appeared to have HIV-specific immune responses similar to those seen in nonprogressive disease (Rosenberg, et. al, Science, 1997; 278:1447-1450). The company believes that the production of all three b-chemokines (MIP-1a, MIP-1b and RANTES) was affected after these individuals were treated with REMUNE. Recent studies in infected individuals have suggested that b-chemokine production is associated with decreased risk of AIDS or death (Ullum, et.al., Journal of Infectious Disease, 1998; 17:331-336). The company is currently conducting placebo-controlled clinical trials to further examine the effects of REMUNE in subjects concurrently treated with highly active antiviral drug therapy. In clinical trials conducted to date with REMUNE, with or without antiviral drug therapy, the most frequently reported side effects include local transient pain, soreness and redness at the site of injection, muscle aches, fatigue and headache.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T cell responses for the treatment of HIV, autoimmune diseases and cancer. The Company is conducting clinical trials for its immune-based therapies for HIV, rheumatoid arthritis, psoriasis, multiple sclerosis, colon cancer and brain cancer and preclinical studies for melanoma and prostate cancers. In addition, the Company is developing a targeted delivery technology for gene therapy which is designed to enable the intravenous injection of genes for delivery directly to the liver. The Company's gene therapy program is currently focused on diseases of the liver and is in preclinical studies for the treatment of hemophilia and hepatitis.
NOTE: The Immune Response Corporation news releases are available at no charge through the company's automated attendant 800 number at 800-491-0153. News releases are also available through PR Newswire's Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: imnr.com.
This news release contains forward-looking statements. Actual results could vary materially from those expected due to a variety of risk factors, including the uncertainty of successful completion of clinical trials, and those risks set forth from time to time in The Immune Response Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1997. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
SOURCE: The Immune Response Corporation
--------------------------------------------------------------------------------
More Quotes and News: Immune Response Corp (Nasdaq:IMNR - news)
|
